Home > Qtrly Results > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Quarterly Results Analysis [Dec2025]

GLENMARK PHARMACEUTICALS is part of below Screeners ↓
Best 1M Momentum Mid Cap Stocks
AD     Remove this Ad

GLENMARK PHARMACEUTICALS Quarterly Results

Consolidated Dec2025
UnAudited
Sep2025
UnAudited
Jun2025
UnAudited
Mar2025
UnAudited
Dec2024
UnAudited
Sep2024
UnAudited
Jun2024
UnAudited
Mar2024
UnAudited
Revenues ₹3,901 Cr ₹6,047 Cr ₹3,264 Cr ₹3,256 Cr ₹3,388 Cr ₹3,434 Cr ₹3,244 Cr ₹3,063 Cr
Expenses ₹3,031 Cr ₹3,687 Cr ₹2,684 Cr ₹2,695 Cr ₹2,787 Cr ₹2,832 Cr ₹2,656 Cr ₹2,559 Cr
Operating Income ₹870 Cr ₹2,360 Cr ₹581 Cr ₹561 Cr ₹600 Cr ₹602 Cr ₹588 Cr ₹504 Cr
Other Income ₹44 Cr ₹201 Cr ₹26 Cr ₹12 Cr ₹31 Cr ₹39 Cr ₹31 Cr ₹773 Cr
Interest ₹41 Cr ₹66 Cr ₹58 Cr ₹67 Cr ₹52 Cr ₹48 Cr ₹40 Cr ₹149 Cr
Depreciation ₹154 Cr ₹141 Cr ₹130 Cr ₹125 Cr ₹123 Cr ₹120 Cr ₹118 Cr ₹151 Cr
Profit Before Tax ₹534 Cr ₹967 Cr ₹96 Cr ₹8 Cr ₹456 Cr ₹473 Cr ₹462 Cr ₹531 Cr
Profit After Tax ₹403 Cr ₹610 Cr ₹47 Cr ₹4 Cr ₹348 Cr ₹354 Cr ₹340 Cr ₹-1,239 Cr
EPS ₹14.29 ₹21.63 ₹1.66 ₹0.16 ₹12.33 ₹12.55 ₹12.06 ₹-43.17
Industry Peers & Returns1W1M1Y
GLENMARK PHARMACEUTICALS 4.9% 6% 63.6%
SUN PHARMACEUTICAL INDUSTRIES 0.3% 9% 8.6%
DIVIS LABORATORIES 1.9% 5.9% 12.6%
CIPLA 1.6% 1.8% -7.9%
TORRENT PHARMACEUTICALS 0.6% 9.5% 45%
DR REDDYS LABORATORIES -1.5% 5.7% 14.5%
MANKIND PHARMA 9.9% 5.8% -2%
ZYDUS LIFESCIENCES 1.6% 4.2% 6%
LUPIN 2.5% 7% 21.9%

GLENMARK PHARMACEUTICALS Quarterly Revenues

Revenues
Q-o-Q

-35.49 %

Y-o-Y

15.15 %

Quarters Revenues % Change
Dec2025 ₹3,901 Cr
-35.49
Sep2025 ₹6,047 Cr
85.23
Jun2025 ₹3,264 Cr
0.25
Mar2025 ₹3,256 Cr
-3.88
Dec2024 ₹3,388 Cr
-1.35
Sep2024 ₹3,434 Cr
5.84
Jun2024 ₹3,244 Cr
5.92
Mar2024 ₹3,063 Cr -

GLENMARK PHARMACEUTICALS Quarterly Operating Profit

Operating Profit
Q-o-Q

-63.14 %

Y-o-Y

44.90 %

Quarters Operating Profit % Change
Dec2025 ₹870 Cr
-63.14
Sep2025 ₹2,360 Cr
306.45
Jun2025 ₹581 Cr
3.47
Mar2025 ₹561 Cr
-6.53
Dec2024 ₹600 Cr
-0.28
Sep2024 ₹602 Cr
2.33
Jun2024 ₹588 Cr
16.63
Mar2024 ₹504 Cr -
Operating Margins
Q-o-Q

-42.85 %

Y-o-Y

25.85 %

Quarters Operating Margin% % Change
Dec2025 22.3%
-42.85
Sep2025 39.02%
119.46
Jun2025 17.78%
3.19
Mar2025 17.23%
-2.77
Dec2024 17.72%
1.08
Sep2024 17.53%
-3.31
Jun2024 18.13%
10.08
Mar2024 16.47% -

GLENMARK PHARMACEUTICALS Quarterly Profit After Tax

Profit After Tax(PAT)
Q-o-Q

-33.94 %

Y-o-Y

15.86 %

Quarters Profit After Tax % Change
Dec2025 ₹403 Cr
-33.94
Sep2025 ₹610 Cr
1,199.54
Jun2025 ₹47 Cr
971.46
Mar2025 ₹4 Cr
-98.74
Dec2024 ₹348 Cr
-1.82
Sep2024 ₹354 Cr
4.19
Jun2024 ₹340 Cr
Positive
Mar2024 ₹-1,239 Cr -
PAT Margins
Q-o-Q

2.38 %

Y-o-Y

0.68 %

Quarters PAT Margin(%) % Change
Dec2025 10.34 %
2.38
Sep2025 10.1 %
601.39
Jun2025 1.44 %
1,007.69
Mar2025 0.13 %
-98.73
Dec2024 10.27 %
-0.48
Sep2024 10.32 %
-1.62
Jun2024 10.49 %
Positive
Mar2024 -40.44 % -

GLENMARK PHARMACEUTICALS Quarterly Earnings Per Share (EPS)

EPS
Q-o-Q

-33.93 %

Y-o-Y

15.90 %

Quarters EPS % Change
Dec2025 ₹14.29
-33.93
Sep2025 ₹21.63
1,203.01
Jun2025 ₹1.66
937.50
Mar2025 ₹0.16
-98.70
Dec2024 ₹12.33
-1.75
Sep2024 ₹12.55
4.06
Jun2024 ₹12.06
Positive
Mar2024 ₹-43.17 -

You may also like the below Video Courses